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A B S T R A C T
Objective: Although not formally supported by guidelines, random glucose testing (RGT) is frequently
used to screen for gestational diabetesmellitus (GDM). Results on test accuracy are inconclusive. The aim
of this study was to systematically review the literature and calculate summary estimates of accuracy
measures of RGT as screening test for GDM.
Study design: Systematic review to identify studies comparing RGT to oral glucose tolerance testing
before 32 weeks of pregnancy. A systematic search without language restrictions was performed in
MEDLINE (1950 till April 2008) and EMBASE (1980 to April 2008). Study selection and data extraction
were performed by two independent reviewers. Outcome measures were summary estimates of test
accuracy of RGT.
Results: Six studies were included, reporting on 3537 women. Due to the small number of studies and
heterogeneity, no summary estimates of test accuracy were calculated. Reported sensitivities and
speciﬁcities of individual studies varied. For 100% sensitivity, speciﬁcity was around 40%. For sensitivity
of 60% speciﬁcity was at most 80%. When speciﬁcity approached 100%, sensitivity dropped to 20–30%.
Conclusion: Available evidence on the accuracy of RGT to test for GDM is limited. Based on studies in our
systematic review, we consider single random glucose measurement inadequate to screen for GDM.
 2010 Elsevier Ireland Ltd.
Contents lists available at ScienceDirect
European Journal of Obstetrics & Gynecology and
Reproductive Biology
journa l homepage: www.e lsev ier .com/ locate /e jogrb
Open access under the Elsevier OA license. 1. Introduction
Gestational diabetes mellitus (GDM) is a metabolic complica-
tion that occurs in 2–9% of all pregnancies and is associated with
increased neonatal and maternal morbidity [1]. Treatment of GDM
improves perinatal as well as maternal outcome [2,3]. Whether
screening for GDM will result in reduction of maternal and
neonatal morbidity remains to be established. The majority of
international diabetes associations, however, advocate screening
for GDM as desirable [4].§ Parts of the results of this study were presented as a poster on the International
Workshop Conference on Gestational Diabetes: Diagnosis and Classiﬁcation in
Pasadena, USA, June 2008. The results of this study were presented as a poster on
the annual meeting of the Society for Gynecologic Investigation in Glasgow,
Scotland, March 2009.
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Open access under the Elsevier OA license. Currently there is no consensus on the optimal approach to
screen for GDM [4,5]. Several international guidelines recommend
either a one-step 75 g oral glucose tolerance test (OGTT) approach,
or a two-step approach in which a 50 g glucose challenge test is
performed, followed by an OGTT in the event of an abnormal test
result [6–9]. Results of the HAPO study support the usefulness of
the former [1].
Although not supported in clinical guidelines, various other
tests are used to screen for GDM. One of these is the random
glucose test (RGT). A national survey from the UK showed that 52%
of the respondents used random glucose measurement to test for
GDM [10]. Results from a Dutch survey showed similar results. In
46% of the participants random glucose testing was the most
frequently used method to screen for GDM (M. van Leeuwen, MD,
unpublished data, 2009).
The RGT is a simple, fast and inexpensive test which measures
plasma glucose at a random point in time, irrespective of the time
of the last meal and without any speciﬁc preparation. There seem
to be only a few studies on the accuracy of the RGT as a screening
test for GDM. Results of these individual studies suggest that
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and false negative test results, although results are not conclusive
[11–13]. The use of inadequate screening methods can result in
unidentiﬁed cases of GDM and therefore preventablematernal and
neonatal morbidity. In addition, it can result in avoidable health
care costs due to testing strategies that result in false positive
cases. An accurate evidence-based method for screening could
ameliorate the process of diagnosis and management of GDM,
resulting in reduction of the rate of serious perinatal complications
and maternal morbidity as well as in reduction of healthcare costs.
As high accuracy, especially high sensitivity, is an important
prerequisite for screening procedures, the RGT should not be used
as screening test for GDM if test accuracy is indeed insufﬁcient,
even if the test is simple and inexpensive. If, on the other hand, the
accuracy of the RGT is sufﬁcient, more complex screening tests for
GDM could be abandoned. The aim of this study was to
systematically review the literature and to calculate summary
estimates of accuracy measures of the RGT in pregnant women in
order to assess its suitability to screen for GDM.
2. Materials and methods
2.1. Literature search
A medical librarian (JL) undertook a systematic search in the
electronic databases MEDLINE (1950 – April 2008) and EMBASE
(1980 to April 2008) to identify studies reporting on the RGT in
pregnant women. In accordance with recommendations for
Cochrane systematic reviews of diagnostic accuracy we initially
searched broadly for the target disease (GDM) and the index test
(RGT) using both free-text words and Subject Headings [14]. No
methodological ﬁlter for diagnostic accuracy studies or any other
restriction was applied as this can lead to omission of relevant
papers [14,15]. To ﬁnd diagnostic accuracy papers that did not
mention random glucose test in the title and/or abstract we also
searched EMBASE for target disease combined with Subject
Headings for diagnostic studies. Similar diagnostic index terms
are not available for MEDLINE.
We systematically inspected reference lists, conducted a ‘‘cited
reference search’’ in Web of Science, applied ‘‘related articles/ﬁnd
similar feature’’ in PubMed and EMBASE, and contacted authors of
primary studies for further published trials. We downloaded all
references identiﬁed into Reference Manager1 software (version
11.0). Duplicate studies were excluded.
2.2. Study selection
Two reviewers (MvL and YY) independently screened titles and
abstracts of all retrieved studies. If either reviewer concluded that
the article would possibly fulﬁll eligibility criteria, we obtained the
full text publication. Based on the full text manuscripts, the two
reviewers selected studies according to predeﬁned criteria. Eligible
studies compared the RGT to the 75 or 100 g oral glucose tolerance
test (OGTT) (reference test) in pregnant women before 32weeks of
gestation and reported sufﬁcient data to construct a two-by-two
table of test performance. Studies that did not report sufﬁcient data
to construct a two-by-two by table, but for which data could
possibly be obtained from the authors, were also evaluated. Final
in-/exclusion decisions were made by comparing results of both
reviewers. Disagreement was resolved by consensus or by
consulting a third reviewer (BWM).
2.3. Data extraction
Data were extracted using a pre-designed piloted data
extraction form. We extracted data on study design, samplecharacteristics and test characteristics, including test accuracy.
Data on test accuracy were abstracted as two by two tables cross
classifying results of the RGT with results of the OGTT. In case of
multiple publications of one study, we used all publications to
acquire complete data. The most recent and complete results were
included in the analysis. If there were data missing concerning test
accuracy, we contacted the corresponding author by email or by
letter. Disagreement on data was resolved by discussion and
consensus or by consulting a third reviewer (BWM).
2.4. Study quality
We evaluated methodological quality of selected studies with
QUADAS, a tool for quality assessment of diagnostic accuracy
studies [16]. Included studies were evaluated by two reviewers
(MvL and YY) on 15 items concerning selection, veriﬁcation,
description of tests and of study population.
2.5. Analysis
For all included studies we calculated sensitivity and
speciﬁcity with 95% conﬁdence intervals. To assess heterogeneity
of the results, we plotted sensitivity against 1-speciﬁcity for all
studies in a receiver operating characteristic (ROC) plot. To
calculate summary estimates of sensitivity and speciﬁcity (and
95% conﬁdence intervals), we intended to use a bivariate
regression model. With a bivariate regression model summary
estimates of sensitivity and speciﬁcity can be calculated
simultaneously, accounting for the possible correlation between
these measures [17]. Because of the small number of included
studies, however, and because of the heterogeneity of studies that
were included we considered meta-analysis not appropriate.
Statistical analyses were performed using SPSS 14.0 (SPSS Inc.,
Chicago, IL, USA).
2.6. Diagnosis of GDM
The reference test to diagnose GDMwas either the 75 g or 100 g
OGTT. Various thresholds for an abnormal OGTT are in use. In the
past impaired glucose tolerance (IGT) was considered to be a
condition in between normoglycemia and GDM. Nowadays, the
IGT classiﬁcation is not often used any more. According to, for
example, the WHO or the ADA criteria, women are classiﬁed as
being normoglycemic or as having GDM [6,18]. To be able to
compare the studies by reference test in the systematic review,
original classiﬁcations were sometimes abandoned, and women
classiﬁed as having impaired glucose tolerance in the original
article were classiﬁed as either being normoglycemic or as having
GDM according to currently used criteria [6,18] (Table 1).
3. Results
With the systematic literature search we identiﬁed 322 studies.
Fig. 1 summarizes the process of literature identiﬁcation and study
selection. We selected 27 studies for further reading. Nine authors
were contacted for additional data of which ﬁve authors
responded. Only one author was able to provide additional data.
Eight studies from which no useful data could be obtained were
excluded.We excluded 13 other studies for various reasons (Fig. 1).
The main reason for exclusion was partial or selective veriﬁcation
of the RGT results. Thus, six studies remained for further analysis.
Table 2 displays study quality as evaluated with the adjusted
QUADAS list. Four studies gave a clear description of the RGT and of
the OGTT. The time between the RGT and the OGTT was <14 days
in three studies, between 14 and 28 days in one study and<28 days
in one study. In one study the time between the tests could not be
[()TD$FIG]
Fig. 1. Results of the literature search and study selection.
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Post hoc, the following items were considered to deﬁne a study as
high quality: prospective recruitment, consecutive inclusion of all
pregnant women with adequate description of inclusion criteria,
adequate description of the index test and 100% veriﬁcation of the
index test. None of the studies met all criteria to be labeled as high
quality.
Characteristics of included studies are summarized in Table 1.
In four studies the RGTwas performed only once during pregnancy
[12,13,19,20]. In two studies multiple RGTs were performed
[11,21].
The four studies in which the RGT was performed once during
pregnancy all were prospective cohort studies with consecutive
recruitment of all pregnant women. These studies comprised a
total of 2678 women of whom 217 (8.1%) developed GDM
[12,13,19,20]. In one study separate thresholds for an abnormal
RGT result were set for women who had and who had not eaten
within 2 h of the RGT. Accuracymeasures of the RGTwere reported
for the two thresholds together [19]. The sensitivity reported in the
four studies ranged from 15% (95% CI 8–25%) to 100% (95% CI 75–
100%) depending on the threshold that was applied, with a
corresponding speciﬁcity of 98% (95% CI 97–98%) and 37% (95% CI
35–37%). The study with the best test accuracy had a sensitivity of
64% and a speciﬁcity of 80% [12].
The ﬁfth study that was included was a prospective cohort
study, in which the RGT and the OGTT were both performed
twice [11], and 749 consecutive women underwent both tests in
the ﬁrst trimester of pregnancy. In women with a normal OGTT
result (n = 735), the RGT as well as the OGTT were repeated in
the second trimester. Accuracy measures were calculated
Table 2
Study quality per study of the six included studies assessed with the QUADAS list.
Jowett
et al. [21]
Nasrat
et al. [19]
Mathai
et al. [12]
Tam
et al. [20]
Maegawa
et al. [11]
van Leeuwen
et al. [13]
Patients representative of practice No Yes Yes Yes Yes Yes
Clear description selection criteria Yes Yes Yes Yes Yes Yes
Reference test likely to detect GDM Yes Yes Yes Yes Yes Yes
Time between tests short enough Yes Yes Yes Yes Yes Yes
Complete veriﬁcation Yes Yes Yes Yes Unclear Yes
Consistent reference test Yes Yes Yes Yes Yes Yes
Index and reference test performed independently Yes Yes Yes Yes Yes Yes
Clear description of index test Yes Yes Yes No No Yes
Clear description of reference test Yes Yes Yes No No Yes
RGT interpreted without results OGTT Yes Unknown Unknown Unknown Unknown Yes
OGTT interpreted without results RGT No No Unknown Unknown Unknown No
Clinical data same as practice Yes Yes Yes Unknown No Yes
Unintepretable test results reported Unknown Yes Yes Yes Unknown Yes
Withdrawals explained Unknown Yes Yes Yes Unknown Yes
Intervention between index and reference test No No No No No No
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was 71% (95% CI 46–88%) with corresponding speciﬁcity of 80.3%
(95% CI 79.8–80.6%) for a threshold of 5.3 mmol/L. In the second
trimester sensitivity was reported to be of 38% (95% CI 14–69%)
with a corresponding speciﬁcity of 82.3% (95 CI 82.0–82.6%) for
a threshold of 5.3 mmol/L.
The sixth study that was included was a prospective cohort
study in which 110 women with risk factors for GDM (e.g. poor
obstetric history not further speciﬁed in the original article and
family history of diabetes mellitus) were admitted to the hospital
for ﬁve venous plasma glucose measurements in 24 h at 27–31
weeks of pregnancy [21]. A 75 g OGTT was performed on the same
day. Accuracy measures were calculated for all ﬁve RGT measure-
ments. The accuracy measures that we calculated based on
information from the article did not match with the accuracy
measures reported in the original article. For a threshold of
5.6 mmol/L, the lowest sensitivity of the ﬁve measurements that
we calculated was 25% (95% CI 18–27%) and the highest sensitivity[()TD$FIG]
Fig. 2. ROC plot of the included studies for various thresholds the RGT. Displayed are
the studies of Mathai (~), Nasrat (&), Tam (^), van Leeuwen et al. (&), Maegawa
et al. (*), ﬁrst trimester and (*), second trimester, Jowett (~).was 47% (95% CI 37–56%) with corresponding speciﬁcities of 97%
(95% CI 91–99%) and 74% (95% CI 66–81%).
Sensitivity and speciﬁcity of all studies were plotted in an ROC
space (Fig. 2). We selected one of the ﬁve measurements of the
study by Jowett and colleagues. We selected only one measure-
ment instead of plotting all ﬁve measurements, because plotting
ﬁve measurements would over-represent the study in the graph.
Because of the low number of studies included in our systematic
review and the considerable methodological as well as clinical
differences between the studies, we did not calculate summary
estimates of sensitivity and speciﬁcity and thus could not construct
a summary ROC curve. From the ROC space in Fig. 2, it appears that
for the individual studies for a sensitivity of 100%, speciﬁcity was
around 40% whereas at a sensitivity of 60%, the speciﬁcity was at
most 80%. When speciﬁcity approached 100%, sensitivity dropped
to 20 and 30%.
4. Comment
In this systematic review we evaluated accuracy measures of
the RGT to assess its suitability for diabetes screening in
pregnancy. The sample of available studies was small and showed
considerable heterogeneity. The studies differed from each other
on several pertinent aspects, such as study design, inclusion
criteria and threshold values for an abnormal RGT result (Table 1).
Therefore we did not calculate summary estimates of accuracy
measures or construct a summary ROC curve. Due to different
timing of screening as well as different threshold values and
patient selection it is impossible to directly compare the studies.
We feel that based on the individual studies included in our
systematic review, the sensitivity and speciﬁcity of the RGT are
insufﬁcient to use the test as a screening test for GDM. These
results are in line with recommendations from international
guidelines. This systematic review does not provide evidence on
the potential beneﬁt of screening to reduce perinatal andmaternal
complications of GDM.
We performed an extensive literature search in various
databases without language or any other restrictions. We assume
that we identiﬁed all articles that report on the RGT, although
studies that did not mention the RGT in title, abstract or keywords
might have been missed in our electronic search. Three relevant
studies that were not identiﬁed by our electronic search appeared
to be not included in MEDLINE or EMBASE [22–24]. We were
unable to obtain the full text of one of these studies [22]. Our
attempt to contact the author of the manuscript was not
successful. Since the results of the studies that were included in
this review are already heterogeneous, however, we feel that
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changed our conclusion.
An explanation for the limited number of studies that we found
with our literature search could be publication bias. Publication
bias occurs when studies with positive results aremore likely to be
submitted, or accepted for publication, than studies with negative
or inconclusive results [25]. If publication bias is present, the
accuracy of the RGT reported in this systematic review was most
likely overestimated.
The clinical applicability of a test depends, amongst others, on
the probability of disease that needs further testing (or treatment).
The extent to which the probability of GDM is increased or
decreased compared to the probability prior to testing (pre-test
probability) depends on the accuracy of the screening test as well
as on prevalence of GDM in the population in which the screening
test is being used. The pre-test probability depends amongst others
on characteristics of the population. An approach in which the RGT
could be clinically useful despite moderate measures of sensitivity
and speciﬁcity is if the probability of GDM after testing exceeds the
probability of disease that is required to warrant further testing (or
treatment). Suppose that prevalence of GDM in a population is 3%.
Assuming that the RGT has a sensitivity of 60% with a speciﬁcity of
80%, a positive result of the RGT changes the probability of GDM
from3% to 8.5%, whereas a negative result of the RGTwould change
the probability of GDM from 3% to 1.5%. Both these probabilities
are low. In a population with a prevalence of GDM of 15%, however
(e.g. womenwith risk factors for GDM), a positive result of the RGT
changes the probability of disease from 15% to 35%, whereas a
negative RGT results changes the probability of disease from15% to
8.1%. If the threshold to perform further testing is set for example
at a probability of 20%, the RGT could be clinically useful in the
second population, but not in the ﬁrst population.
The RGT is a relatively easy and fast procedure to screen for
GDM. It requires no speciﬁc preparation such as, for example,
fasting or ingestion of an oral glucose load and the test itself carries
little inconvenience for women. The relative convenience and low
costs of the test might be the reason for its frequent use, albeit not
supported by international guidelines [8]. If a test is used in a
screening setting, however, in general high sensitivity of the test is
mandatory, irrespective of other characteristics such as conve-
nience or costs.
The study by Maegawa was the only one that found a more
favorable combination of sensitivity and speciﬁcity for the RGT in
the ﬁrst trimester [11]. Thresholds for an abnormal RGT were set at
5.3 mmol/L and 5.6 mmol/L, which could explain the relative high
sensitivity, since 5.3 mmol/L is often used as a cut off value for the
fasting glucose test. Furthermore,womenwithanabnormalOGTT in
the ﬁrst trimester are more likely to have diabetes type one or two
that is discovered in pregnancy, rather than GDM. To evaluate the
accuracy of the test to screen forGDM, the accuracy of the test in the
second trimester should be considered. Sensitivity of the test in the
second trimester was considerably lower than in the ﬁrst trimester.
The study by Jowett and colleagues showed that the perform-
ance of the RGT is associatedwith timing of the test. The sensitivity
of the RGT in their study ranged from 25% to 47% for random blood
glucosemeasurement in the samewomen at different times of day.
As pregnancy progresses, plasma glucose levels under fasting
conditions drop whereas plasma glucose levels after a meal
become higher [11]. As the RGT is performed at a random point in
time, peak values after a meal might remain undetected. Indeed
women may have normal blood glucose values with random
glucose testing, but still have unnoticed (asymptomatic) periods of
hyperglycemia [26]. These peaks might contribute to adverse
outcomes in pregnancy and complications during delivery. Combs
et al. showed that fetal macrosomia was related to increased
postprandial glucose levels [27].A series of RGT measurements could partly resolve this issue of
variation in blood glucose values. If random glucose measurement
is, for example, performed ﬁve times a day, using the highest blood
glucose value as the result of the RGT, sensitivity of the RGT might
be improved, though the relatively easy and convenient character
of the test would be lost. A large cohort study by Ostlund and
Hanson evaluated accuracy measures of multiple RGT measure-
ments throughout pregnancy [28]. The highest value of the RGT
measured during pregnancy cross classiﬁed against the result of
the OGTT resulted in a maximum sensitivity of 75.4% with a
corresponding speciﬁcity of 77.9% (threshold value 6.5 mmol/L).
By measuring random blood glucose values on a regular basis in
pregnancy the discriminative capacity of the RGT might thus be
increased.
In conclusion, based on the studies included in our systematic
review, sensitivity and speciﬁcity of the RGT seem to be not
sufﬁcient to be used as a screening test. Therefore, we consider a
single RGTmeasurement an inadequatemethod to screen for GDM.
The potential value of the RGT in screening strategies in which
individual pre-test probabilities based on, for example, patient
characteristics are combinedwith test accuracymeasures could be
evaluated in decision analysis models. If, however, performance of
the RGT then is not increased the RGT has little value for detecting
GDM.
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Appendix A. Veriﬁcation bias
When a screening test is evaluated against a reference test,
ideally all participating patients should undergo both tests.
However, in practice, this is seldom done due to high costs of
the procedure or burden to the patient. If only patients with
veriﬁed screening test results are used to assess the performance of
the screening test, calculated accuracy measures become biased
since patients with veriﬁed disease status are only patients with
abnormal screening test results, which is not a representative
random sample of the population in which the screening test is
being used. The bias that is introduced is called (partial)
veriﬁcation bias.
In the study by van Leeuwen et al., the reference test was not
performed in all patients (predeﬁned protocol). The following
procedure was used to correct for veriﬁcation bias. The OGTT
(reference test) was performed in an arbitrary subset of consecutive
patients with two negative screening test results to determine the
extent to which cases of GDM were missed by the screening tests.
Subsequently results of the OGTT measurements in women who
werenot subjected to anOGTTwere estimatedbasedon resultsof the
M. van Leeuwen et al. / European Journal of Obstetrics & Gynecology and Reproductive Biology 154 (2011) 130–135 135random test and the 50-g glucose screening test as well as on
patient characteristics using multiple logistic regression analysis.
This procedure is called imputation.
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